Mechanisms of acute coronary syndromes and the potential role of statins

Atherosclerosis Supplements

Volumn 2, Issue 1, 2001, Pages 9-14

  Dupuis, Jocelyn ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Coronary; Lesions; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; GATIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; HYPOCHOLESTEROLEMIC AGENT;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ATHEROSCEROTIC PLAQUE RUPTURE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL DIAMETER; CELL VIABILITY; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; CYTOKINE PRODUCTION; DRUG MECHANISM; ENDOTHELIUM LESION; FIBRINOGEN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTIMA; LIFESTYLE; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; RUPTURE; SMOOTH MUSCLE FIBER; THROMBOGENESIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; PATHOPHYSIOLOGY; REVIEW;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0035260193     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(00)00004-0     Document Type: Conference Paper

References (44)

1. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
2. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
3. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on arteriosclerosis, American Heart Association. Circulation. 92:1995;1355-1374.
4. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:(16):2000;1899-1906.
5. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.R. Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:(9):2000;948-954.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
7. Xu X.P., Meisel S.R., Ong H.M., et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 99:1999;993-998.
8. Amento E.P., Ehsani N., Palmer H., Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11:1991;1223-1230.
9. Mach F., Schönbeck U., Bonnefoy J.-Y., Pober J.S., Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 96:1997;396-399.
10. Kinlay S., Selwyn A.P., Libby P., Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J. Cardiovasc. Pharmacol. 32:1998;S62-S66. (suppl 3).
11. Lagrand W.K., Niessen H.W.M., Wolbink G.J., et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 95:1997;97-103.
12. Pietilä K.O., Harmoinen A.P., Jokiniitty J., Pasternack A.I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur. Heart J. 17:1996;1345-1349.
13. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 96:1998;731-733.
14. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin and risk of cardiovascular disease in apparently health men. New Engl. J. Med. 336:1997;973-979.
15. Ridker PM, Rifai N, Pfeffer MA, Sack F, Braunwald E for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100;230-5.
16. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
17. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 353:1999;983.
18. Bernini F., Didoni G., Bonfadini G., et al. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 104:1993;19-26.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339:1998;1349-1357.
21. Pitt B., Mancini G.J.B., Ellis S.G., et al. Pravastatin liitation of atherosclerosis in the coronary arteries (PLAC-1): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26:1995;1133-1139.
22. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
23. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial [see comments]. Circulation. 99:1999;3227-3233.
24. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 31:(3):1998;684-691.
25. Laufs U., Fata v. La, Plutzky J., Liao K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:(12):1998;1129-1135.
26. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33:(1):1999;234-241.
27. Tsuda Y., Satoh K., Kitadai M., et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 122:1996;325-333.
28. Dangas G., Badimon J.J., Smith D.A., et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 33:1999;1294-1304.
29. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effect of atorvastatin on plasma fibrinogen. Lancet. 351:1998;569-570.
30. Beigel Y., Fuchs J., Snir M., et al. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic, parameters, platelet activity and red blood cell morphology. J. Clin. Pharmacol. 31:1991;512-517.
31. Mayer J., Eller T., Brauer P., et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann. Hematol. 64:1992;196-201.
32. Bo M., Bonino F., Neirotti M., et al. Hemorrheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology. 42:1991;106-113.
33. Avellone G., DiGarbo V., Cordova R., et al. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr. Ther. Res. Clin. Exp. 55:1994;1335-1344.
34. Danqas G., Ambrose J.A., Smith D.A. Treatment of hyperlipidemia with pravastatin improves the systemic hemostatic/fibrinolytic profile and decreases throbus formation. Eur. Heart J. 19:1998;808. abstract.
35. Mitropoulos K.A., Armitage J.M., Collins R., et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins, and free fatty acids. Eur. Heart J. 18:1997;235-2341.
36. Davidson M., McKenney J., Stein E., et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 79:1997;L1475-L1481.
37. Isaacsohn J., Setaro J.F., Nicholas C., et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am. J. Cardiol. 74:1994;735-737.
38. Bevilacquua M., Bettica P., Milani M., et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am. J. Cardiol. 79:1997;84-87.
39. Lacoste L., Lam J.Y.T., Hung J., et al. Hyperlipidaemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
40. Lacoste L., Lam Y.J.T. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients. J. Am. Coll. Cardiol. 27:1996;413A. abstract.
41. Dangas G., Ambrose J.A., Smith D.A., et al. Tratment of hypercholesterolaemic patients with and without coronary artery disease with pravastatin decreases thrombus formation under dynamic flow conditions. Eur. Heart J. 35:1998;236.
42. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 100:1999;1958-1963.
43. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 31:1998;684-691.
44. Negre-Aminou P., van Vliet A.K., van Erck M., et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim. Biophys. Acta. 1345:1997;259-268.